$EBS News
Last published 1d ago
- 1d agoEBSEmergent BioSolutions to Participate in Jefferies Global Healthcare ConferenceBusiness WireGAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Jefferies Global Healthcare Conference in London, November 16-19, 2026. Management will present via webcast on November 18 at 8:00am – 8:25am UTC/GMT (3:00am ET). A replay of the presentation will be available on the webcast page li ...
- 1w agoEBSEmergent BioSolutions Inc. 3Q26 Earnings Call - EMERGENT BIOSOLUTIONS INCEarnings Call TranscriptsHello everyone, thank you for joining us and welcome to the Emergent Biosolutions 3rd Quarter 2026 Earnings Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a que
- 1w agoEBSEmergent BioSolutions Inc. - EX-99.1 ER 11.2.26Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 3w agoEBSEmergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. LindahlBusiness WireAppointment of Frank Vargo, VP, Treasurer, to Interim CFO effective January 1, 2027 Emergent BioSolutions Inc. (NYSE:EBS) today announced that Richard S. Lindahl, executive vice president, chief financial officer,
- 3w agoEBSEmergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026Business WireEmergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Monday, November 2, 2026, at 5:00 p.m. eastern time to discuss the financial results for the third quarter of 2026. Participants can access the
- 1mo agoEBSMedia Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing FacilityGlobeNewswireCompany leaders, elected officials and community stakeholders will come together on September 16, 2026 to mark milestone in advanced biopharmaceutical manufacturing CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) --
- 2mo agoEBSEmergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured NotesGlobeNewswireRepurchase reduces unsecured note balance to approximately $364.7 millionManagement to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG, Md., Sept. 03,
- 2mo agoEBSEmergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)GlobeNewswireGAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and
- 2mo agoEBSEmergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal SprayGlobeNewswireStanding offer expands access to opioid overdose emergency treatment across participating federal, provincial and territorial organizations in Canada WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent
- 2mo agoEBSEmergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness DayGlobeNewswireReady to Rescue campaign returns to U.S. college campuses with Release Recovery Founder and CEO Zac Clark Partnership with professional baseball player Davis Schneider seeks to raise awareness of opioid poisoning
- 3mo agoEBSEmergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security EnvironmentGlobeNewswireGAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations
- 3mo agoEBSEmergent BioSolutions Reports Second Quarter 2026 Financial ResultsGlobeNewswireSecond Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash
- 3mo agoEBSEmergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026GlobeNewswireGAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, August 5, 2026, at 5:00 p.m. eastern time to discuss the financial results for the
- 4mo agoEBSEmergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. GovernmentGlobeNewswireGAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic
- 5mo agoEBSEmergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid OverdoseGlobeNewswireGAITHERSBURG, Md., June 04, 2026 (GLOBE NEWSWIRE) -- In honor of National Naloxone Awareness Day on June 6th, Emergent BioSolutions Inc. (NYSE:EBS) is teaming up with Victoria's Voice Foundation – which launched the
- 5mo agoEBSEmergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense StrategyGlobeNewswireGAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for
- 5mo agoEBSEmergent BioSolutions to Participate in Upcoming Investor ConferencesGlobeNewswireGAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that members of the company's senior management team will participate in the following investor conferences:
- 5mo agoEBSEmergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]GlobeNewswireGAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of
- 6mo agoMRNAINONVAXEBSHantavirus cases spark surge in pharma and biotech stocks — here’s whyCNBCThe outbreak of Hantavirus on a cruise ship has led to biotech and pharmaceutical stocks surging on reports of firms developing vaccines.
- 6mo agoEBSEmergent BioSolutions Reports First Quarter 2026 Financial ResultsGlobeNewswireFirst Quarter 2026 Total Revenues of $156.1 millionFirst Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4%First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23%
- 6mo agoEBSEmergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include MpoxGlobeNewswireGAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that Singapore's Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000®
- 6mo agoEBSSABSEmergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142GlobeNewswireGAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (NASDAQ:SABS, SAB BIO)) to support the process
- 6mo agoEBSEmergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save LivesGlobeNewswireStar left fielder joins forces with Emergent to educate the public on the importance of being prepared with NARCAN® Nasal SpraySchneider shares his family's story as part of Emergent's Opioid Crisis Impact Map
- 6mo agoEBSEmergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United StatesGlobeNewswireEmergent's Canton facility will manufacture drug substance and obtains exclusive distribution rights GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today
- 6mo agoEBSEmergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026GlobeNewswireGAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the
- 6mo agoEBSEmergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial FlexibilityGlobeNewswireGAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company has closed on a new credit facility agreement with OrbiMed for a new $150 million term loan.
- 7mo agoEBSEmergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone ProgramGlobeNewswireWINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE:EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN® Nasal Spray
- 7mo agoEBSEmergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose PreparednessGlobeNewswireGAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a series of initiatives designed to help increase access to NARCAN® Nasal Spray and encourage the public
- 7mo agoEBSEmergent BioSolutions Participates in Upcoming International Preparedness ConferencesGlobeNewswireGAITHERSBURG, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global life sciences leader with biodefense and medical countermeasures products, announced today that members of its
- 7mo agoEBSEmergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical CountermeasuresGlobeNewswireGAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia
- 8mo agoEBSEmergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of DirectorsGlobeNewswireGAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings
- 8mo agoEBSEmergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireFourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million
- 8mo agoEBSEmergent BioSolutions Announces New $50 Million Stock Repurchase ProgramGlobeNewswireGAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company's common stock on or
- 8mo agoEBSEmergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health PreparednessGlobeNewswireWINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the
- 9mo agoEBSEmergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray MultipacksGlobeNewswireApproval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication GAITHERSBURG, Md., Feb. 12, 2026
- 9mo agoEBSEmergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026GlobeNewswireGAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the
- 10mo agoEBSEmergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday PreparednessGlobeNewswireSince the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN® carrying case
- 10mo agoEBSEmergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year TransformationGlobeNewswireGAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions, Inc. (NYSE:EBS) announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in late December 2025
- 10mo agoEBSEmergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026GlobeNewswireGAITHERSBURG, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE:EBS) announced it has received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply
- 10mo agoEBSEmergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in AfricaGlobeNewswireGAITHERSBURG, Md. and PARIS and ADDIS ABABA, Ethiopia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE:EBS) announced a collaboration agreement with PANTHER to provide additional financial support
- 10mo agoEBSEmergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026GlobeNewswireGAITHERSBURG, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that Joe Papa, president and chief executive officer, will provide a company presentation during the 44th
- 11mo agoEBSEmergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada SiteGlobeNewswireGAITHERSBURG, Md., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA)
- 11mo agoEBSEmergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone AccessGlobeNewswireGAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE:EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN® (naloxone HCl)
- 12mo agoEBSEmergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of DirectorsGlobeNewswireGAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) announced today that Dr. Louis W. Sullivan will retire from the company's Board of Directors effective November 14 after 19 years of
- 1y agoEBSEmergent BioSolutions Reports Third Quarter 2025 Financial ResultsGlobeNewswireThird Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 millionThird Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22%Third Quarter 2025 Gross Margin % of 54%
- 1y agoEBSEmergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. PreparednessGlobeNewswireGAITHERSBURG, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the results of a new survey1 of approximately 250 U.S. policy opinion leaders showing that nearly two-thirds
- 1y agoEBSEmergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025GlobeNewswireGAITHERSBURG, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, October 29, 2025, at 5:00 pm eastern time to discuss the financial results for the
- 1y agoEBSEmergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving NaloxoneGlobeNewswireGAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions Inc. (NYSE:EBS)
- 1y agoEBSEmergent BioSolutions Secures $29 Million in MCM Product Orders from International Government PartnerGlobeNewswireGAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has secured new purchase orders from an international government partner for a multi-product supply
- 1y agoEBSEmergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply ChainGlobeNewswireGAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development